SCHEMBL20467136

SCHEMBL20467136

CCCCCc1ccc(OC)nc1OC

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 4/20 0.44
ALOX5 P09917 6/20 0.41
PTGS2 P35354 4/20 0.41
TDP1 Q9NUW8 2/20 0.41
POLB P06746 1/20 0.41
TXNRD1 Q16881 3/20 0.39
GSR P00390 1/20 0.39
KCNH2 Q12809 1/20 0.38
MEN1 O00255 1/20 0.38
TP53 P04637 1/20 0.38
CYP3A4 P08684 1/20 0.38
MAPT P10636 1/20 0.38
TYR P14679 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
PPARA Q07869 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19236925 0.98 PDE10A (0.45) PDE10AALOX5PTGS2TDP1POLB
SCHEMBL20467095 0.81 ALOX5 (0.41) ALOX5PTGS2TDP1KCNH2MEN1
SCHEMBL21230758 0.80 ALOX5 (0.40) ALOX5PTGS2TDP1KCNH2MEN1
SCHEMBL9908276 0.80 POLB (0.52) PDE10ATDP1POLBTXNRD1MEN1
SCHEMBL24306090 0.75 SMPD1 (0.43) TDP1POLBTXNRD1GSR
SCHEMBL1848182 0.74 POLB (0.46) PDE10ATDP1POLBMEN1MAPT
SCHEMBL18291529 0.74 POLB (0.46) PDE10ATDP1POLBMEN1TSHR
SCHEMBL6408365 0.74 POLB (0.50) PTGS2TDP1POLBMEN1MAPT
SCHEMBL675903 0.72 ALOX5 (0.49) ALOX5PTGS2TDP1KCNH2PPARA
SCHEMBL26612262 0.72 PDE10A (0.44) PDE10AALOX5PTGS2TXNRD1GSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10308975-B2 Substituted imidazo[1,2-a]pyrazines as luciferase substrates PROMEGA CORPORATION (US) 2019-06-04 US disclosed
US-20180223330-A1 COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180223330-A1 COELENTERAZINE ANALOGUES GLB1, SI, TCF7L2 PDE10A 341/4885ALOX5 3906/4885PTGS2 2136/4885
US-10308975-B2 Substituted imidazo[1,2-a]pyrazines as luciferase substrates AADAC, PGLS, GLB1 PDE10A 317/4885ALOX5 2791/4885PTGS2 632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.